Drug name - Xermelo
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7709493 | TERSERA | 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use |
Dec, 2027
(5 years from now) | |
| US7553840 | TERSERA | 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use |
Dec, 2027
(5 years from now) | |
| US8193204 | TERSERA | Solid forms of (S)-ethyl 2-amino-3-(4-(2-amino-6-((R)-1- (4-chloro-2-(3-methyl-1H-pyrazol-1-YL)phenyl)2,2,2-trifluoroethoxy)-pyrimidin-4-YL)phenyl)propanoate and methods of their use |
Feb, 2031
(8 years from now) | |
| CN101809018A | TERSERA | Solids Forms Of ( S) -Ethyl 2-Amin0-3- (4- (2 -Amino- 6- ( (R) -1- (4-Chl0R0-2- O-Methyl-Ih-Pyrazol- 1-Yl) Phenyl) -2, 2, 2-Trifluorethoxy) -Pyrimidin-4-Yl) Phenyl) Propanoate |
Sep, 2028
(6 years from now) | |
| CN101809018B | TERSERA | (S)--2-Amino--3-(4-(2-Amino--6-((R) -1-(4-Chloro--2-(3-Methyl--1H-Pyrazol--1-Yl) Phenyl) -2, 2, 2-Trifluoro-Ethyoxyl)-Pyrimidin--4-Yl) Phenyl) Ethyl Propionate In Solid Form And Methods Of Use Thereof |
Sep, 2028
(6 years from now) | |
| IN200903374P4 | TERSERA | 4-Phenyl-6-(2,2,2-Trifluoro-1-Phenylethoxy) Pyrimidine-Based Compounds And Methods Of Their Use |
Dec, 2027
(5 years from now) | |
| IN282661B | TERSERA | 4-Phenyl-6-(2,2,2- Trifluoro-1- Phenylethoxy) Pyrimidine-Based Compounds And Methods Of Their Use |
Dec, 2027
(5 years from now) | |
| IN201002222P1 | TERSERA | Solids Forms Of (S)-Ethyl 2-Amin0-3-(4-(2-Amino-6-(R)-1-(4-Chl0R0-2-0-Methyl-Ihpyrazol- 1-Yl) Phenyl)-2, 2, 2-Trifluorethoxy) -Pyrimidin-4-Yl) Phenyl) Propanoate |
Sep, 2028
(6 years from now) | |
| IN281019B | TERSERA | Crystalline Forms Of Tryptophan Hydroxylase Inhibitor And Pharmceutically Acceptable Salts Thereof |
Sep, 2028
(6 years from now) | |
| EP3176159B1 | TERSERA | 4-Phenyl-6-(2,2,2-Trifluoro-1-Phenylethoxy)Pyrimidine-Based Compounds And Methods Of Their Use |
Dec, 2027
(5 years from now) | |
| EP2589600B1 | TERSERA | 4-Phenyl-6-(2,2,2-Trifluoro-1-Phenylethoxy)Pyrimidine-Based Compounds And Methods Of Their Use |
Dec, 2027
(5 years from now) | |
| EP2589600A1 | TERSERA | 4-Phenyl-6-(2,2,2-Trifluoro-1-Phenylethoxy)Pyrimidine-Based Compounds And Methods Of Their Use |
Dec, 2027
(5 years from now) | |
| EP3176159A1 | TERSERA | 4-Phenyl-6-(2,2,2-Trifluoro-1-Phenylethoxy)Pyrimidine-Based Compounds And Methods Of Their Use |
Dec, 2027
(5 years from now) | |
| EP2091940B1 | TERSERA | 4-Phenyl-6-(2,2,2-Trifluoro-1-Phenylethoxy)Pyrimidine-Based Compounds And Methods Of Their Use |
Dec, 2027
(5 years from now) | |
| EP2091940B3 | TERSERA | 4-Phenyl-6-(2,2,2-Trifluoro-1-Phenylethoxy)Pyrimidine-Based Compounds And Methods Of Their Use |
Dec, 2027
(5 years from now) | |
| EP2091940A2 | TERSERA | 4-Phenyl-6-(2,2,2-Trifluoro-1-Phenylethoxy)Pyrimidine-Based Compounds And Methods Of Their Use |
Dec, 2027
(5 years from now) | |
| EP2203444B1 | TERSERA | Solids Forms Of ( S) -Ethyl 2-Amin0-3- (4- (2 -Amino- 6- ( (R) -1- (4-Chl0R0-2- O-Methyl-Ih-Pyrazol- 1-Yl) Phenyl) -2, 2, 2-Trifluorethoxy) -Pyrimidin-4-Yl) Phenyl) Propanoate |
Sep, 2028
(6 years from now) | |
| EP2203444A1 | TERSERA | Solids Forms Of ( S) -Ethyl 2-Amin0-3- (4- (2 -Amino- 6- ( (R) -1- (4-Chl0R0-2- O-Methyl-Ih-Pyrazol- 1-Yl) Phenyl) -2, 2, 2-Trifluorethoxy) -Pyrimidin-4-Yl) Phenyl) Propanoate |
Sep, 2028
(6 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7968559 | TERSERA | Methods of using 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds |
Dec, 2027
(5 years from now) | |
| US8653094 | TERSERA | Solid forms of (S)-ethyl 2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)-pyrimidin-4-yl)phenyl)propanoate and methods of their use |
Dec, 2028
(6 years from now) | |
Drugs and Companies using TELOTRISTAT ETIPRATE ingredient
Treatment: The treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (ssa) therapy in adults inadequately controlled by ssa therapy
Dosage: TABLET;ORAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| EQ 250MG BASE | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.